Liège, Belgium, August 22, 2022 – 17:45 CET – Mithra Pharmaceuticals SA (Euronext Brussels: MITRA) (the “Company” or “Mithra”), a company dedicated to women’s health, today announces that following the first drawdown made by the Company under the loan facility entered into with funds managed by Highbridge Capital Management, LLC (“Highbridge”) and funds managed by Whitebox Advisors, LLC (“Whitebox”, and jointly with Highbridge, each a “Lender”), a new part of the loans was provided in kind by the Lenders against the issue of new shares.
Following the drawing, part of the loans (including accrued interest, if any, and the option prepayment amount) was contributed in kind for a total amount of EUR 4,829,523.30 by issuing of 799,861 new shares at a price respectively of (i) EUR 6.03 per share for the 733,662 shares issued to Highbridge and (ii) EUR 6.08 per share for the 66,199 shares issued to Whitebox.